Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling-Reference-Cited by-同舟云学术

Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling

Published:2024-08-23 Issue: Volume: Page:
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Taylor Kurt^ORCID,Latimer Nicholas R.,Douglas Thomas,Hatswell Anthony J.,Ho Sophia,Okorogheye Gabriel,Borril John,Chen Clara,Kim Inkyu,Bertwistle David

Funder

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40273-024-01423-6.pdf

Reference58 articles.

1. National Cancer Institute. Immunotherapy to treat cancer [Internet]. [cited 2023 Mar 16]. Available from: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy

2. Quinn C, Garrison LP, Pownell AK, Atkins MB, de Pouvourville G, Harrington K, et al. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. J Immunother Cancer. 2020;8(2): e000648.

3. Sculpher M, Claxton K. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty—when is there sufficient evidence? Value Health. 2005;8(4):433–46.

4. Kamgar F, Ho S, Hawe E, Brodtkorb T. A review of treatment-effect waning methods for immuno-oncology therapies in national institute for health and care excellence technology appraisals. ISPOR EU 2022 [Internet]. 2022 Nov 6; Available from: https://www.ispor.org/docs/default-source/euro2022/6367isporkamgarposter21oct2022-pdf.pdf?sfvrsn=f86dde27_0

5. Trigg LA, Melendez-Torres GJ, Abdelsabour A, Lee D. Treatment effect waning assumptions: a review of national institute of health and care excellence technology appraisals. Value Health J Int Soc Pharmacoecon Outcomes Res. 2024;S1098–3015(24):02348–9.